Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
|Slideshows|June 1, 2023
MDD Research Update
Author(s)Brian Miller, MD, PhD, MPH
Looking to stay up to date on MDD research? This research collection reviews outcomes on metabolic abnormalities, biomarkers, and more.
Advertisement
Advertisement
Related to this article
Rethink “treatment-resistant depression” by adopting difficult-to-treat depression, verifying adequate trials, and stratifying drivers like trauma and inflammation to improve outcomes.
Vortioxetine eases depression in older adults, while cognitive gains stay mixed—showing selective boosts in attention and processing speed, not consistent global improvement.
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Blood-Based Biomarkers for Alzheimer Disease: Accuracy, Limits, and Confounders
4
Should Postpartum Psychosis Be Included in the DSM?
5